samedan logo
 
 
spacer
home > pmps > summer 2002 > surfactant - therapy, excipient and humectant
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Surfactant - Therapy, Excipient and Humectant

Surfactant replacement therapy for the treatment and prevention of neonatal respiratory distress syndrome (RDS) has been a major success story in respiratory care over the past decade. Animal-derived and synthetic surfactants are now available commercially throughout the world and there are several others in development. Surfactants are currently providing a miracle-like contribution towards dramatically improving the survival rate of critically ill infants with less than 30 weeks' gestation.

However, these advances may well be overshadowed by progressions in formulation technology that will make synthetic surfactants available for a number of other conditions. After the first few days from birth, adequate surfactant function is vitally important for optimal lung function. Surfactant dysfunction arising from a variety of mechanisms may contribute to a number of conditions. Surfactant therapy has been examined in a number of these with varying effects.

They include acute respiratory distress syndrome (ARDS) (1), respiratory syncytial virus bronchiolitis in infants (2), chronic bronchitis (3), chronic obstructive pulmonary disease (4), asthma (5,15), respiratory infections (6) and cystic fibrosis (7). Understanding the different roles of endogenous surfactant and the dysfunctions observed in these conditions must be a consideration when designing an effective therapy. In addition to opposing surface tension forces within the alveolus to maintain airway stability, surfactant has also been reported to promote mucociliary clearance (8), bind or neutralise aeroallergens, pollens, bacteria and other particulates (9,10), and oppose airway oedema (11).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Derek Woodcock, Technical Services Director for Britannia Pharmaceuticals Ltd. Derek Woodcock is Technical Services Director for Britannia Pharmaceuticals Ltd., where he is responsible for the company's medical, clinical and development projects. Derek oversees specific technical projects from the formulation definition stage to clinical evaluation and registration.
He currently has technical responsibility for establishing Britannia's phospholipid and surfactant research, which also covers some novel delivery technologies for internal and out-licensing opportunities. In addition to technical expertise, he has particular knowledge in the area of drug licensing and registration.
Derek gained a BPharm degree in Pharmacy from The School of Pharmacy in London and an MBA from Kingston University. He is also a registered Pharmacist.

spacer
Derek Woodcock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific.

Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement